Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for <italic style="font-style: italic">HER2</italic>-positive metastatic breast cancer

WU Yanan; WU Fang; HOU Yanhong

doi:10.6039/j.issn.1001-0408.2024.02.14

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer

更新时间：2024-01-24

- Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 2, Pages: 204-209(2024)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.02.14
  CLC： R956;R979.1
- Published：30 January 2024，
  
  Received：29 July 2023，
  
  Revised：25 December 2023，
扫描看全文
武亚楠,吴方,侯艳红.德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析 ^Δ[J].中国药房,2024,35(02):204-209.

WU Yanan,WU Fang,HOU Yanhong.Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer[J].ZHONGGUO YAOFANG,2024,35(02):204-209.
武亚楠,吴方,侯艳红.德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析 ^Δ[J].中国药房,2024,35(02):204-209. DOI： 10.6039/j.issn.1001-0408.2024.02.14.

WU Yanan,WU Fang,HOU Yanhong.Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer[J].ZHONGGUO YAOFANG,2024,35(02):204-209. DOI： 10.6039/j.issn.1001-0408.2024.02.14.

摘要

目的

评估德曲妥珠单抗（T-DXd）对比恩美曲妥珠单抗（T-DM1）二线治疗

HER2

阳性转移性乳腺癌的经济性，为临床用药方案的选择及医疗卫生决策提供依据。

方法

基于DESTINY-Breast03试验构建分区生存模型，以3周为循环周期，模拟至患者终身。以质量调整生命年（QALY）作为产出指标并计算增量成本-效果比（ICER），再利用敏感性分析验证基础分析结果的稳健性，以此来比较T-DXd与T-DM1二线治疗

HER2

阳性转移性乳腺癌的经济性。

结果

在以3倍我国2022年人均国内生产总值（GDP）为意愿支付阈值（257 094元/QALY）的前提下，使用T-DXd方案的患者在获得增量效用（0.69 QALYs）的同时也需要支付更多成本，ICER值为1 850 478.40元/QALY。单因素敏感性分析结果显示，对ICER影响较大的因素有无进展生存期状态效用值、T-DXd价格、成本贴现率等，但这些参数在合理范围内波动均不能使基础分析结果发生翻转。概率敏感性分析结果显示，当WTP的阈值上升为1 500 400元/QALY时，T-DXd方案具有经济性的概率为50%。情境分析结果也验证了基础分析结果的稳健性。

结论

在以3倍我国人均GDP为意愿支付阈值的前提下，与T-DM1方案相比，T-DXd二线治疗

HER2

阳性转移性乳腺癌不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of trastuzumab deruxtecan（T-DXd） versus trastuzumab emtansine （T-DM1） in the second-line treatment of

HER2

-positive metastatic breast cancer， and to provide a basis for the selection of clinical medication regimen and medical and health decisions.

METHODS

Based on the clinical trial DESTINY-Breast03， a partitioned survival model was constructed， with a cycle of 3 weeks as the simulation of patients’ lifetime. The incremental cost-effectiveness ratio （ICER） was calculated by using quality-adjusted life years （QALY） as output indicators， and sensitivity analysis was used to verify the robustness of the basic analysis results； the cost-effectiveness of the second-line treatment for

HER2

-positive metastatic breast cancer was compared between T-DXd and T-DM1.

RESULTS

Under the premise of taking 3 times China’s per capita gross domestic product （GDP） in 2022 as the willingness-to-pay threshold （257 094 yuan/QALY）， the T-DXd group also needed to pay more cost compared with T-DM1 group while obtaining incremental utility （0.69 QALYs）， and the ICER value was 1 850 478.40 yuan/QALY. The results of univariate sensitivity analysis showed that progression-free survival state utility value， T-DXd price， cost discount rate were factors that had a great influence on ICER value， but these parameters could not flip the basic analysis results within a reasonable range. In the probability sensitivity analysis， when the threshold of willingness-to-pay rose to 1 500 400 yuan/QALY， the probability of economic activity was 50% in the T-DXd regimen. The results of the scenario analysis also verified the robustness of the original research results.

CONCLUSIONS

Under the premise of 3 times China’s per capita GDP as the WTP threshold， compared with T-DM1， T-DXd is not cost-effective in the second-line treatment of

HER2

-positive metastatic breast cancer.

关键词

德曲妥珠单抗恩美曲妥珠单抗HER2阳性转移性乳腺癌分区生存模型成本-效用分析

Keywords

trastuzumab emtansineHER2-positive metastatic breast cancerpartitioned survival modelcost-utility analysis

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

LEI S Y，ZHENG R S，ZHANG S W，et al. Global patterns of breast cancer incidence and mortality：a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun，2021，41（11）：1183-1194.

CAO M M，LI H，SUN D Q，et al. Cancer burden of major cancers in China：a need for sustainable actions[J]. Cancer Commun，2020，40（5）：205-210.

SUN Y，LI W Q，LI A J，et al. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative，HER2-positive breast cancer patients[J]. Cancer Manag Res，2019，11：3153-3162.

李阁，谷瑞雪，刘旭，等. Her-2阳性乳腺癌靶向治疗药物的研究进展[J]. 肿瘤学杂志，2020，26（1）：1-6.

LI G，GU R X，LIU X，et al. Research progress in treatment of Her-2-positive breast cancer with targeted agents[J]. J Chin Oncol，2020，26（1）：1-6.

CAMERON D，PICCART-GEBHART M J，GELBER R D，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer：final analysis of the HERceptin Adjuvant （HERA） trial[J]. Lancet，2017，389（10075）：1195-1205.

HURVITZ S A，HEGG R，CHUNG W P，et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer：updated results from DESTINY-Breast03，a randomised，open-label，phase 3 trial[J]. Lancet，2023，401（10371）：105-117.

IM S A，GENNARI A，PARK Y H，et al. Pan-Asian adapted ESMO clinical practice guidelines for the diag-nosis，staging and treatment of patients with metastatic breast cancer[J]. ESMO Open，2023，8（3）：101541.

GRADISHAR W J，MORAN M S，ABRAHAM J，et al. NCCN guidelines® insights：breast cancer，version 4.2023[J]. J Natl Compr Canc Netw，2023，21（6）：594-608.

YANG J P，HAN J Q，ZHANG Y L，et al. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer[J]. Front Pharmacol，2022，13：924126.

ZHU Y W，LIU K，WANG M，et al. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer：a cost-effectiveness analysis[J]. Breast，2022，66：191-198.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：27-46.

LIU G E. China guidelines for pharmacoeconomic evaluations 2020[M]. Beijing：China Market Press，2020：27-46.

中国临床肿瘤学会.中国临床肿瘤学会（CSCO）乳腺癌诊疗指南 2023[Ｍ]. 北京：人民卫生出版社，2023：87.

Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology（CSCO）guidelines for the diagnosis and treatment of breast cancer 2023[M]. Beijing：People’s Medical Publishing House，2023：87.

SAURA C，OLIVEIRA M，FENG Y H，et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens：phase Ⅲ NALA trial[J]. J Clin Oncol，2020，38（27）：3138-3149.

WU Y，DONG Z，WANG J F，et al. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China：a cost-effectiveness analysis[J]. BMJ Open，2022，12（11）：e065299.

WANG H，ZENG C X，LI X，et al. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer[J]. Future Oncol，2019，15（2）：181-191.

高红婷，胡梦雪，贾琳琳，等. 信迪利单抗联合化疗一线治疗晚期或复发性非小细胞肺癌的成本-效用分析[J]. 中国药房，2022，33（15）：1854-1859.

GAO H T，HU M X，JIA L L，et al. Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced or recurrent non-small cell lung cancer[J]. China Pharm，2022，33（15）：1854-1859.

YANG Q，YU X X，ZHANG W. Health variations among breast-cancer patients from different disease states：evidence from China[J]. BMC Health Serv Res，2020，20（1）：1033.

DOI T，SHITARA K，NAITO Y，et al. Safety，pharmacokinetics，and antitumour activity of trastuzumab deruxtecan（DS-8201），a HER2-targeting antibody-drug conjugate，in patients with advanced breast and gastric or gastro-oesophageal tumours：a phase 1 dose-escalation study[J]. Lancet Oncol，2017，18（11）：1512-1522.

李欣. 从肿瘤药物的慈善赠药谈我国的患者援助项目[J]. 西部学刊，2022（13）：172-176.

LI X. Discussion on patient assistance projects in China from the perspective of charitable donation of tumor drugs[J]. J West，2022（13）：172-176.

OGITANI Y，AIDA T，HAGIHARA K，et al. DS-8201a，a novel HER2-targeting ADC with a novel DNA topoiso-merase Ⅰ inhibitor，demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res，2016，22（20）：5097-5108.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

Pharmacoeconomic evaluation of clopidogrel versus aspirin for secondary prevention of ischemic stroke

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Introduction of measurement methods of health utility for cancer patients

Related Author

LIU Guoqiang

NIU Mengna

GUO Shan

GAO Shengnan

FENG Bing

GAO Ning

NIE Xuyang

QI Ran

Related Institution

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Clinical Pharmacy， the Third Hospital of Hebei Medical University

Dept. of Clinical Pharmacology Research， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， Huangpu Branch， Shanghai Ninth People’s Hospital， Shanghai Jiaotong University School of Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer

DOI：10.6039/j.issn.1001-0408.2024.02.14

摘要

Abstract

关键词

Keywords

references